Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%Martin Reck, Julie R. Brahmer, Andrew Robinson et al.|Journal of Clinical Oncology|2021Cited by 1.1k